193
Participants
Start Date
July 23, 2015
Primary Completion Date
May 22, 2018
Study Completion Date
May 22, 2018
Sirukumab 50 mg
Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
Placebo
Participants will receive matching placebo on Day 1, 28 and 56.
Birmingham
Little Rock
Bellflower
Glendale
Lemon Grove
Orange
Santa Ana
Torrance
Wildomar
Atlanta
Decatur
Chicago
Edgewood
Baltimore
Grand Rapids
Lebanon
Brooklyn
New York
Staten Island
Columbus
Oklahoma City
Houston
Plano
Salt Lake City
Edmonton
Chatham
Hamilton
Toronto
Bełchatów
Bydgoszcz
Chełmno
Gorlice
Lublin
Karelia
Moscow
Nizny Novgorod
Rostov-on-Don
Saint Petersburg
Saratov
Saratov Region
Tomsk
Yaroslavl
Edinburgh
Glasgow
Oxford
Redruth
Janssen Research & Development, LLC
INDUSTRY